US 12,329,749 B2
Low concentration delivery of an ergoline derivative for treatment of a headache
Ralph Solarski, Alpharetta, GA (US); and Robert Edward Malone, Northborough, MA (US)
Assigned to RELEVALE, INC., Alpharetta, GA (US)
Filed by Relevale, Inc., Alpharetta, GA (US)
Filed on Jul. 1, 2021, as Appl. No. 17/365,750.
Application 17/365,750 is a continuation of application No. 16/359,313, filed on Mar. 20, 2019, granted, now 11,083,712.
Claims priority of provisional application 62/645,212, filed on Mar. 20, 2018.
Prior Publication US 2021/0322392 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); A61M 5/20 (2006.01); A61M 5/28 (2006.01); A61M 5/32 (2006.01); A61P 25/06 (2006.01); A61M 5/31 (2006.01)
CPC A61K 31/437 (2013.01) [A61M 5/2033 (2013.01); A61M 5/281 (2013.01); A61M 5/3202 (2013.01); A61P 25/06 (2018.01); A61M 2005/206 (2013.01); A61M 2005/3139 (2013.01)] 15 Claims
OG exemplary drawing
 
1. An ergoline derivative containing medicament comprising dihydroergotamine or a pharmaceutically acceptable salt thereof, wherein the medicament is disposed in an auto-injector device, the device comprising:
a syringe containing the medicament;
a hollow injection needle operably coupled to a distal end of the syringe; a dosing mechanism operably adjacent to a proximal end of the syringe; and a trigger mechanism operably coupled to the dosing mechanism,
wherein the trigger mechanism, when actuated, causes the dosing mechanism to advance the syringe and the injection needle, discharging the medicament though the injection needle; and
wherein the medicament comprises a pH of between about 3 and about 8; and
wherein the ergoline derivative is present in a concentration range of about 0.3 mg/mL to about 1.5 mg/mL.